BC
LGND icon

Bartlett & Co’s Ligand Pharmaceuticals LGND Stock Holding History

Bartlett & Co’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-53
Closed -$4K – 771
2019
Q1 		$4K Hold
53
– – ﹤0.01% 623
2018
Q4 		$4K Hold
53
– – ﹤0.01% 632
2018
Q3 		$9K Hold
53
– – ﹤0.01% 607
2018
Q2 		$7K Hold
53
– – ﹤0.01% 616
2018
Q1 		$5K Hold
53
– – ﹤0.01% 653
2017
Q4 		$5K Hold
53
– – ﹤0.01% 632
2017
Q3 		$4K Buy
+53
New +$4.2K ﹤0.01% 630

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Bartlett & Co's LGND Position: Q2 2019 in Review

Bartlett & Co sold out of Ligand Pharmaceuticals (LGND) in Q2 2019, closing a stake of 53 shares — an estimated $4K sold.

Bartlett & Co first reported a position in LGND in Q3 2017 and held it in 7 quarters. The position peaked at $9K in Q3 2018. 305 funds tracked by Wall St. Rank hold LGND as of Q2 2019.

  • Bartlett & Co reported no remaining Ligand Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Bartlett & Co sold 53 Ligand Pharmaceuticals shares in Q2 2019, an estimated $4K.
  • Bartlett & Co first reported a position in Ligand Pharmaceuticals in Q3 2017 and held it in 7 quarters.
  • Bartlett & Co's Ligand Pharmaceuticals position peaked at $9K in Q3 2018.
  • 305 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q2 2019.

Based on Bartlett & Co's 13F filing for Q2 2019, filed 24 Jul 2019.